Congress trades in GSK (GSK)
6 of the members we track disclosed 15 purchases of GSK between 2022-01-14 and 2026-03-30, and 10 sales. Here is what the stock did afterwards.
Every purchase is measured over the three months after the transaction date, against XLV — the ETF standing in for Healthcare & Pharma — over exactly the same dates. The second figure is the one that carries information: the first mostly reflects what the sector did. How GSK was classified.
How these buys are tagged
2 of these purchases were made by a member whose own committee oversees Healthcare & Pharma.
| Buys | Number | Return after 3 months | vs. sector | Beat their sector |
|---|---|---|---|---|
| All buys | 15 | -3.3% | -4.3% | 33% |
| Notable (committee-flagged) | 2 | Too few buys to measure | ||
| Unaligned (no committee overlap) | 13 | -3.4% | -3.7% | 38% |
| Cluster, excl. mega-caps | 0 | Too few buys to measure | ||
| Not clustered, excl. mega-caps | 15 | -3.3% | -4.3% | 33% |
Who bought the most
- Virginia Foxx — 8 buys
- Lisa C. McClain — 3 buys
- Alan Armstrong — 1 buy
- Bruce Westerman — 1 buy
- Val T. Hoyle — 1 buy
Every disclosed purchase
| Member | Bought disclosed |
Signal | Price | 1W | 1M | 3M | vs sector |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-30 2026-07-21 |
Notable | $54.23 | +3.9% | -5.2% | -2.6% | -14.4% |
| Lisa C. McClain | 2025-10-30 2025-11-21 |
Unaligned | $46.94 | +0.3% | +2.0% | +7.9% | +1.3% |
| Lisa C. McClain | 2025-08-04 2025-09-12 |
Unaligned | $37.68 | +0.1% | +4.5% | +23.0% | +14.4% |
| Lisa C. McClain | 2025-06-17 2025-08-13 |
Unaligned | $39.72 | -2.6% | -8.2% | +0.8% | -1.8% |
| Bruce Westerman | 2025-03-03 2025-04-16 |
Unaligned | $37.95 | +6.2% | -0.8% | +9.8% | +21.0% |
| Val T. Hoyle | 2024-11-18 2025-09-12 |
Unaligned | $33.69 | +1.4% | +0.0% | +7.4% | +5.3% |
| Tommy Tuberville | 2023-04-03 2023-05-12 |
Notable | $35.95 | +5.3% | +2.5% | -1.8% | -2.4% |
| Virginia Foxx | 2022-08-16 2022-09-08 |
Unaligned | $35.26 | -4.3% | -12.0% | -8.4% | -7.8% |
| Virginia Foxx | 2022-08-10 2022-09-08 |
Unaligned | $38.30 | -9.4% | -16.7% | -15.4% | -14.3% |
| Virginia Foxx | 2022-08-09 2022-09-08 |
Unaligned | $40.03 | -11.9% | -21.3% | -19.5% | -20.7% |
| Virginia Foxx | 2022-08-05 2022-09-08 |
Unaligned | $40.57 | -11.2% | -21.5% | -18.7% | -18.2% |
| Virginia Foxx | 2022-07-06 2022-08-05 |
Unaligned | $43.11 | -5.1% | -5.9% | -29.5% | -27.2% |
| Virginia Foxx | 2022-04-08 2022-05-04 |
Unaligned | $46.64 | -0.7% | -5.5% | -9.2% | -0.8% |
| Virginia Foxx | 2022-02-22 2022-03-07 |
Unaligned | $42.69 | -2.7% | +1.4% | +5.4% | +2.2% |
| Virginia Foxx | 2022-01-14 2022-02-04 |
Unaligned | $45.47 | -0.8% | -2.6% | +1.9% | -1.5% |
Prices are the closing price on the transaction date, not what was paid: filings never disclose an execution price. Blank figures mean the window has not elapsed yet. Sales are not scored — a sale closes a position rather than opening one — so the 10 disclosed sales of GSK are not in this table.
Download the data behind this page, or read how every figure is calculated. Trades in GSK are a small part of the full rankings, which score each member across everything they bought.
Data last updated .